Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibrx BiosciencesINBX +6.47%6 14-Day RSI is 64.58 as of Aug. 13, 2026. GuruFocus rates INBX with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Inhibrx Biosciences ranks worse than 86.72% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Inhibrx Biosciences 14-Day RSI Related Terms
INBX vs JBIO, NVAX, AVLN: 14-Day RSI Comparison
For the Biotechnology subindustry, Inhibrx Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx Biosciences (INBX) has a 14-Day RSI of 64.58 as of Aug. 13, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Inhibrx Biosciences and its competitors. According to the industry distribution chart, Inhibrx Biosciences ranks #1228 out of 1416 companies in the Biotechnology industry, placing it in the top 86.7%.
Is Inhibrx Biosciences' 14-Day RSI too high?
Inhibrx Biosciences' current 14-Day RSI is 64.58. The Biotechnology industry median 14-Day RSI is 52.10. Inhibrx Biosciences' value of 64.58 is 24% above this industry median. Based on the distribution chart, Inhibrx Biosciences ranks #1228 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inhibrx Biosciences has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inhibrx Biosciences' 14-Day RSI compare to JBIO and NVAX?
According to the Biotechnology industry distribution chart, Inhibrx Biosciences ranks #1228 out of 1416 companies for 14-Day RSI. This places Inhibrx Biosciences in the lower half of its industry. The industry median 14-Day RSI is 52.10. Inhibrx Biosciences' value of 64.58 is 24% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 52.10, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibrx Biosciences's current 14-Day RSI of 64.58 is 24% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Inhibrx Biosciences and its competitors. For the Biotechnology industry, the median 14-Day RSI is 52.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibrx Biosciences's current 14-Day RSI is 64.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibrx Biosciences stock overvalued right now?
Inhibrx Biosciences (INBX) has a current 14-Day RSI of 64.58. The current 14-Day RSI is 64.58 and 24% above the Biotechnology industry median of 52.10. Inhibrx Biosciences' overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Inhibrx Biosciences (INBX), the current 14-Day RSI is 64.58 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
6GF Score
Get the complete analysis for INBX
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBX has been successfully added to your 
